Why the study?
Do calcium antagonists provide a superior antihypertensive response compared to other antihypertensive agents in elderly and black patients with mild to moderate essential hypertension?
Do calcium antagonists provide a superior antihypertensive response compared to other antihypertensive agents in elderly and black patients with mild to moderate essential hypertension?
Calcium antagonists do not show preferential efficacy in the elderly, but they do provide a greater antihypertensive response in black patients compared to beta-blockers or ACE inhibitors.
Answers are grounded in this paper and cite their sources.
Does not justify preferential calcium antagonist use in elderly hypertensives; leaves open race-specific responses pending randomized confirmation.
Calcium antagonists are now recommended as monotherapy for the treatment of mild to moderate essential hypertension by the Joint National Committee (JNC) on the Detection, Evaluation, and Treatment of High Blood Pressure. Based on a statement in the 1988 JNC report that black and elderly patients tend to respond better to calcium antagonists, we reviewed the literature to examine the predictive value of age and race to the antihypertensive response of calcium antagonists. The majority of studies we reviewed failed to substantiate the JNC statement and wellpromulgated reports in the literature suggesting preferential action of calcium antagonists in the elderly, or their superiority when compared with diuretics, βadrenergic blockers, and angiotensin-converting enzyme inhibitors. Although not noted by the JNC, pretreatment blood pressure appeared to be an important predictor of the antihypertensive response to calcium antagonists. The literature reviewed indicates that calcium antagonists have comparable efficacy in black and white hypertensive patients. However, the limited comparative studies reviewed support the JNC statement that, as with diuretics, blacks have a greater antihypertensive response with calcium antagonists than with βadrenergic blockers or angiotensin-converting enzyme inhibitors. (Arch Intern Med. 1991;151:2154-2162)
No takes yet. Share an insight, caveat, or question.
W. Zing (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: